Does the media refer more to CLRB or SBFM?

In the previous week, Sunshine Biopharma had 11 more articles in the media than Cellectar Biosciences. MarketBeat recorded 12 mentions for Sunshine Biopharma and 1 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.75 beat Sunshine Biopharma's score of 0.09 indicating that Cellectar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sunshine Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TVRD or SBFM?

In the previous week, Sunshine Biopharma had 11 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 12 mentions for Sunshine Biopharma and 1 mentions for Tvardi Therapeutics. Sunshine Biopharma's average media sentiment score of 0.09 beat Tvardi Therapeutics' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sunshine Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BFRI or SBFM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer BFRI or SBFM?

In the previous week, Sunshine Biopharma had 7 more articles in the media than Biofrontera. MarketBeat recorded 12 mentions for Sunshine Biopharma and 5 mentions for Biofrontera. Biofrontera's average media sentiment score of 0.49 beat Sunshine Biopharma's score of 0.09 indicating that Biofrontera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sunshine Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CTXR or SBFM?

In the previous week, Sunshine Biopharma had 11 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 12 mentions for Sunshine Biopharma and 1 mentions for Citius Pharmaceuticals. Sunshine Biopharma's average media sentiment score of 0.09 beat Citius Pharmaceuticals' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sunshine Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CABR or SBFM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caring Brands 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Sunshine Biopharma (SBFM) Competitors

$0.43 -0.27 (-38.57%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$0.37 -0.06 (-13.26%)

As of 06:41 AM Eastern

Compare

SBFM vs. CLRB, TVRD, BFRI, CTXR, and CABR

Should you buy Sunshine Biopharma stock or one of its competitors? Sunshine Biopharma's main competitors and comparable companies include Cellectar Biosciences (CLRB), Tvardi Therapeutics (TVRD), Biofrontera (BFRI), Citius Pharmaceuticals (CTXR), and Caring Brands (CABR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Sunshine Biopharma compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Cellectar Biosciences has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-185.35%	-115.42%
Sunshine Biopharma	-17.94%	-26.36%	-20.60%

In the previous week, Sunshine Biopharma had 11 more articles in the media than Cellectar Biosciences. MarketBeat recorded 12 mentions for Sunshine Biopharma and 1 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.75 beat Sunshine Biopharma's score of 0.09 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sunshine Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sunshine Biopharma has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A
Sunshine Biopharma	$36.31M	0.05	-$5.97M	-$10.15	N/A

Cellectar Biosciences presently has a consensus target price of $11.00, indicating a potential upside of 685.71%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cellectar Biosciences is more favorable than Sunshine Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Cellectar Biosciences has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by insiders. Comparatively, 1.7% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Cellectar Biosciences and Sunshine Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Sunshine Biopharma compare to Tvardi Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Tvardi Therapeutics has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
Sunshine Biopharma	-17.94%	-26.36%	-20.60%

In the previous week, Sunshine Biopharma had 11 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 12 mentions for Sunshine Biopharma and 1 mentions for Tvardi Therapeutics. Sunshine Biopharma's average media sentiment score of 0.09 beat Tvardi Therapeutics' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sunshine Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sunshine Biopharma has higher revenue and earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	2.02	-$18.21M	-$2.79	N/A
Sunshine Biopharma	$36.31M	0.05	-$5.97M	-$10.15	N/A

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by insiders. Comparatively, 1.7% of Sunshine Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Tvardi Therapeutics has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Tvardi Therapeutics currently has a consensus target price of $18.00, suggesting a potential upside of 1,566.67%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Tvardi Therapeutics is more favorable than Sunshine Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Tvardi Therapeutics beats Sunshine Biopharma on 9 of the 17 factors compared between the two stocks.

How does Sunshine Biopharma compare to Biofrontera?

Biofrontera (NASDAQ:BFRI) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 8.1% of Biofrontera shares are held by company insiders. Comparatively, 1.7% of Sunshine Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Biofrontera has a net margin of -13.78% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Sunshine Biopharma	-17.94%	-26.36%	-20.60%

In the previous week, Sunshine Biopharma had 7 more articles in the media than Biofrontera. MarketBeat recorded 12 mentions for Sunshine Biopharma and 5 mentions for Biofrontera. Biofrontera's average media sentiment score of 0.49 beat Sunshine Biopharma's score of 0.09 indicating that Biofrontera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sunshine Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sunshine Biopharma has lower revenue, but higher earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.33	-$10.54M	-$0.45	N/A
Sunshine Biopharma	$36.31M	0.05	-$5.97M	-$10.15	N/A

Biofrontera has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Summary

Biofrontera beats Sunshine Biopharma on 8 of the 15 factors compared between the two stocks.

How does Sunshine Biopharma compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Citius Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, Sunshine Biopharma has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Citius Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 923.12%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Citius Pharmaceuticals is more favorable than Sunshine Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Citius Pharmaceuticals has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-59.57%	-34.47%
Sunshine Biopharma	-17.94%	-26.36%	-20.60%

In the previous week, Sunshine Biopharma had 11 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 12 mentions for Sunshine Biopharma and 1 mentions for Citius Pharmaceuticals. Sunshine Biopharma's average media sentiment score of 0.09 beat Citius Pharmaceuticals' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sunshine Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 5.0% of Citius Pharmaceuticals shares are held by insiders. Comparatively, 1.7% of Sunshine Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Sunshine Biopharma has higher revenue and earnings than Citius Pharmaceuticals. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A
Sunshine Biopharma	$36.31M	0.05	-$5.97M	-$10.15	N/A

Summary

Sunshine Biopharma beats Citius Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Sunshine Biopharma compare to Caring Brands?

Caring Brands (NASDAQ:CABR) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

42.0% of Sunshine Biopharma shares are held by institutional investors. 14.6% of Caring Brands shares are held by insiders. Comparatively, 1.7% of Sunshine Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sunshine Biopharma has higher revenue and earnings than Caring Brands. Caring Brands is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caring Brands	N/A	N/A	-$6.28M	-$0.74	N/A
Sunshine Biopharma	$36.31M	0.05	-$5.97M	-$10.15	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caring Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Sunshine Biopharma had 12 more articles in the media than Caring Brands. MarketBeat recorded 12 mentions for Sunshine Biopharma and 0 mentions for Caring Brands. Sunshine Biopharma's average media sentiment score of 0.09 beat Caring Brands' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Caring Brands	Neutral
Sunshine Biopharma	Neutral

Caring Brands has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat Caring Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caring Brands	N/A	-1,153.12%	-322.63%
Sunshine Biopharma	-17.94%	-26.36%	-20.60%

Summary

Sunshine Biopharma beats Caring Brands on 9 of the 12 factors compared between the two stocks.

Get Sunshine Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SBFM vs. The Competition

Export

Metric	Sunshine Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.02M	$12.36B	$7.20B	$13.40B
Dividend Yield	N/A	2.64%	2.53%	16.36%
P/E Ratio	-0.04	800.12	274.66	25.98
Price / Sales	0.05	784.50	558.21	73.13
Price / Cash	N/A	86.17	76.82	53.72
Price / Book	0.01	10.71	10.81	6.27
Net Income	-$5.97M	$2.83B	$3.50B	$382.01M
7 Day Performance	-35.48%	-1.36%	-1.84%	-1.60%
1 Month Performance	-61.61%	-6.15%	-6.35%	-4.63%
1 Year Performance	-97.43%	-6.06%	3.07%	-0.95%

Sunshine Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SBFM Sunshine Biopharma	1.5389 of 5 stars	$0.43 -38.6%	N/A	-97.4%	$3.02M	$36.31M	N/A	50	Trending News Gap Down High Trading Volume
CLRB Cellectar Biosciences	2.9205 of 5 stars	$1.56 +3.0%	$11.00 +607.4%	-70.7%	$14.70M	N/A	N/A	11	Gap Up
TVRD Tvardi Therapeutics	2.5658 of 5 stars	$1.05 -3.2%	$18.00 +1,622.5%	-97.3%	$14.27M	$7.14M	N/A	80
BFRI Biofrontera	1.0973 of 5 stars	$0.95 +1.9%	N/A	-9.0%	$14.24M	$46.18M	N/A	94	News Coverage
CTXR Citius Pharmaceuticals	1.9678 of 5 stars	$0.50 +4.4%	$5.00 +896.0%	-62.0%	$13.78M	N/A	N/A	20	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SBFM) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sunshine Biopharma (SBFM) Competitors

SBFM vs. CLRB, TVRD, BFRI, CTXR, and CABR

How does Sunshine Biopharma compare to Cellectar Biosciences?

Summary

How does Sunshine Biopharma compare to Tvardi Therapeutics?

Summary

How does Sunshine Biopharma compare to Biofrontera?

Summary

How does Sunshine Biopharma compare to Citius Pharmaceuticals?

Summary

How does Sunshine Biopharma compare to Caring Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM vs. The Competition

Sunshine Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sunshine Biopharma (SBFM) Competitors

SBFM vs. CLRB, TVRD, BFRI, CTXR, and CABR

How does Sunshine Biopharma compare to Cellectar Biosciences?

Is CLRB or SBFM more profitable?

Does the media refer more to CLRB or SBFM?

Which has better earnings & valuation, CLRB or SBFM?

Do analysts prefer CLRB or SBFM?

Which has more risk & volatility, CLRB or SBFM?

Do institutionals & insiders believe in CLRB or SBFM?

Summary

How does Sunshine Biopharma compare to Tvardi Therapeutics?

Is TVRD or SBFM more profitable?

Does the media favor TVRD or SBFM?

Which has higher valuation & earnings, TVRD or SBFM?

Do institutionals & insiders hold more shares of TVRD or SBFM?

Which has more volatility and risk, TVRD or SBFM?

Do analysts prefer TVRD or SBFM?

Summary

How does Sunshine Biopharma compare to Biofrontera?

Do analysts recommend BFRI or SBFM?

Do institutionals and insiders have more ownership in BFRI or SBFM?

Is BFRI or SBFM more profitable?

Does the media prefer BFRI or SBFM?

Which has preferable valuation and earnings, BFRI or SBFM?

Which has more volatility and risk, BFRI or SBFM?

Summary

How does Sunshine Biopharma compare to Citius Pharmaceuticals?

Which has more risk & volatility, CTXR or SBFM?

Do analysts recommend CTXR or SBFM?

Is CTXR or SBFM more profitable?

Does the media prefer CTXR or SBFM?

Do institutionals & insiders have more ownership in CTXR or SBFM?

Which has stronger earnings & valuation, CTXR or SBFM?

Summary

How does Sunshine Biopharma compare to Caring Brands?

Do insiders & institutionals have more ownership in CABR or SBFM?

Which has better valuation & earnings, CABR or SBFM?

Do analysts recommend CABR or SBFM?

Does the media favor CABR or SBFM?

Is CABR or SBFM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM vs. The Competition

Sunshine Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools